High anti tumor activity against rhabdomyosarcoma cells and low normal cells cytotoxicity of heat shock protein 90 inhibitors, with special emphasis on 17-[2-(pyrrolidin-1-yl)ethyl]-aminno-17-demethoxygeldanamycin

Journal of Physiology and Pharmacology

Volumn 60, Issue 3, 2009, Pages 161-166

  Lukasiewicz, E ^a   Miekus, K ^a   Kijowski, J ^a   Gozdzik, J ^a   Wilusz, M ^a   Bobis Wozowicz, S ^a   Wiecha, O ^a   Majka, Marcin ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

17AAG; 17AEP GA; Geldanamycin; HSP90; MET receptor; Rhabdomyosarcoma

Indexed keywords

17 [2 (PYRROLIDIN 1 YL)ETHYL]AMINNO 17 DEMETHOXYGELDANAMYCIN; 17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; MESSENGER RNA; NUCLEAR PROTEIN; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CYTOTOXICITY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; ENDOTHELIUM CELL; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MESENCHYME CELL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SARCOMA CELL; TUMOR CELL; TUMOR GROWTH;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BENZOQUINONES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOTAXIS; EPITHELIAL CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MATRIX METALLOPROTEINASE 2; MESENCHYMAL STEM CELLS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA;

EID: 70350225462     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127: 679-695.
2. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-772.
3. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002; 21: 1159-1166. (Pubitemid 34185232)
4. Kim S, Kang J, Hu W, Evers BM, Chung DH. Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas. Int J Cancer 2003; 103: 352-359. (Pubitemid 36076428)
5. Ochel HJ, Eichhorn K, Gademann G. Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones. Cell Stress Chaperones 2001; 6: 105-112. (Pubitemid 32522216)
6. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995; 36: 305-315.
7. Modi S, Stopeck AT, Gordon M, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007; 25: 5410-5417. (Pubitemid 350232217)
8. Syme R, Bewick M, Stewart D, et al. The role of depletion of dimethyl sulfoxide before autografting: on hematologic recovery, side effects, and toxicity. Biol Blood Marrow Transplant 2004; 10: 135-141. (Pubitemid 38145867)
9. Breitfeld PP, Meyer WH. Rhabdomyosarcoma: new windows of opportunity. Oncologist 2005; 10: 518-527.
10. Lesko E, Gozdzik J, Kijowski J, Jenner B, Wiecha O, Majka M. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo. Anticancer Drugs 2007; 18: 1173-1181. (Pubitemid 47480742)
11. Jankowski K, Kucia M, Wysoczynski M, et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res 2003; 63: 7926-7935. (Pubitemid 37466729)
12. Taulli R, Scuoppo C, Bersani F, et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006; 66: 4742-4749.
13. Sausville EA, Tomaszewski JE. Clinical development of 17- allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003; 3: 377-383.
14. Chiosis G. Discovery and development of purine-scaffold Hsp90 inhibitors. Curr Top Med Chem 2006; 6: 1183-1191. (Pubitemid 44110929)
15. Newcomb EW, Lukyanov Y, Schnee T, et al. The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo. Anticancer Drugs 2007; 18: 875-882. (Pubitemid 47220705)
16. Meyer PN, Roychowdhury S, Kini AR, Alkan S. HSP90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells. Leuk Res 2008; 32: 143-149. (Pubitemid 350100847)
17. Georgakis GV, Li Y, Younes A. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol 2006; 135: 68-71. (Pubitemid 44337664)
18. George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005; 105: 1768-1776. (Pubitemid 40223701)
19. Lang SA, Klein D, Moser C, et al. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 2007; 6: 1123-1132. (Pubitemid 46554583)
20. Maulik G, Kijima T, Ma PC, et al. Modulation of the c- Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002; 8: 620-627. (Pubitemid 34193985)
21. Park JW, Yeh MW, Wong MG, et al. The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines. J Clin Endocrinol Metab 2003; 88: 3346-3353.
22. Xie Q, Gao CF, Shinomiya N, et al. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene 2005; 24: 3697-3707. (Pubitemid 40826869)
23. Mendes O, Kim HT, Lungu G, Stoica G. MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2. Clin Exp Metastasis 2007; 24: 341-351. (Pubitemid 47124935)